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Sustained transgene expression is required for the success of cell transplant-based gene therapy. Most widely used are lentiviral-
basedvectorswhichintegrateintothehostgenomeandtherebymaintainsustainedtransgeneexpression.Thisrequiresintegration
into the nuclear genome, and potential risks include activation of oncogenes and inactivation of tumor suppressor genes. Plasmids
have been used; however lack of sustained expression presents an additional challenge. Here we used the pCAG-PyF101-eGFP
plasmid to deliver the human GDNF gene to cat neural progenitor cells (cNPCs). This vector consists of a CAGG composite
promoter linked to the polyoma virus mutant enhancer PyF101. Expression of an episomal eGFP reporter and GDNF transgene
were stably maintained by the cells, even following induction of diﬀerentiation. These genetically modiﬁed cells appear suitable
for use in allogeneic models of cell-based delivery of GDNF in the cat and may ﬁnd veterinary applications should such strategies
prove clinically beneﬁcial.
1.Introduction
Transplantation of neural stem or progenitor cells for
treatment of neurodegenerative diseases is an approach that
has shown considerable promise in a variety of animal
models (as reviewed by [1–4]). One region of the central
nervous system (CNS) where particular progress has been
notable is the retina, where cells of this type have been
shown to integrate into immature neonatal [5], as well as
maturedegenerative[6]hostrats,andexhibitmorphological
proﬁles suggestive of resident local neurons. Studies of this
typehavealsobeenextendedtononrodentspecies,including
the immature Brazilian opossum [7] and the dystrophic
Abyssinian cat [8]. Throughout this work, transplantation
of neural progenitor cells (NPCs) to the retina has been
shown to be well tolerated in allogeneic models [9]a n d
even some xenogeneic situations [7]. Survival of NPCs as
grafts does not therefore routinely require systemic immune
suppression, although exceptions certainly exist, as has been
clearly documented [10, 11].
The results of the above work with NPC transplantation
to the eye, together with a substantial volume of related stud-
ies, have helped to nurture enthusiasm for the translational
development of this technology. The goal of these eﬀorts is
the treatment of a range of conditions aﬀecting the retina,
forwhichcurrentclinicaloutcomesfrequentlyleaveroomfor
improvement and many of which remain incurable, despite
impressive recent pharmacological advances. The abilities of
NPCs to be expanded in culture, integrate into retinal tissue,
survive without immune suppression, and diﬀerentiate in
p r e s u m p t i v er e t i n a lc e l lt y p e sa l lr e p r e s e n tf a v o r a b l ec h a r -
acteristics for a donor cell type to possess. However, the2 Stem Cells International
apparent inability of NPCs to generate photoreceptor cells
[6],atleastinsizeablenumbers[7],doesrestricttheiruseasa
means of cell replacement in the retina. This constraint does
not mitigate their potential eﬀectiveness in an alternate role,
namely, as delivery vehicles for neuroprotective cytokines.
Neurotrophic factors contribute greatly to promoting
cell survival of speciﬁc neurons in the CNS. Among the
most potent for this purpose are glial cell line-derived
neurotrophic factor (GDNF), brain-derived neurotrophic
factor (BDNF), and ciliary neurotrophic factor (CNTF).
Among these, GDNF is known to be antiapoptotic [12]
in the brain [13, 14], spinal cord [15], and retina [16–
19]. Receptors for GDNF are known to be expressed by
cells of the mature retina [16, 19, 20]. Several types of
stem and progenitor cells have been genetically modiﬁed
to overexpress neurotrophic factors, resulting in enhanced
levels of growth factor secretion and an enhanced ability to
rescueretinalneuronsandpreservevisualfunctionfollowing
transplantation to animal models of retinal injury and
disease [21]. Neural progenitor cells derived from the human
cerebral cortex that had been genetically modiﬁed to over-
express GDNF showed considerable eﬃciency in delaying
neural degeneration [22], and the same strategy has been
investigated in the retina [23].
Viralvectorshavebeenwidelyusedfortransgenedelivery
[24] and are currently regarded as the most eﬃcient method.
However their use is limited due to safety issues, DNA
loading capacity, and diﬃculties in scale-up for production.
An alternate approach that does not require integration
of the gene into the genome and therefore avoids the
risk of insertional mutagenesis is the use of autonomously
replicating plasmids or episomes (as reviewed by [25]). In
episomally replicating plasmids, sequences of incorporated
DNA (generally viral) enable the plasmid to replicate
extrachromosomally. This poses several advantages over
integrating systems: (1) the transgene cannot be interrupted
or subjected to regulatory constraints that often occur with
integration into cellular DNA; (2) higher transfection eﬃ-
ciency can be obtained than with chromosome-integrating
plasmids; (3) episomes display a low mutation rate and tend
nottorearrange[26];(4)episomallyreplicatingsystemshave
the ability to transfer larger amounts of DNA [27].
In the present study, we explore the eﬃciency of non-
viral plasmid vector pCAG-PyF101-eGFP mediated gene
delivery in NPCs of feline origin. This plasmid consists of
the CAGG composite promoter derived from the fusion of
thehumancytomegalovirusmajorimmediateearlyenhancer
(HCMV-MIE), chicken β-actin promoter, and rabbit globin
intronsequence[28]thatdrivestheexpressionofatransgene
linked to a downstream internal ribosomal entry site (IRES)
and a drug selection cassette. This plasmid has previously
been shown to resist gene silencing in murine and human
embryonic stem cells [29, 30]. Importantly, the inclusion of
a virus mutant polyoma enhancer sequence, PyF101, ensures
continuous transgene expression in the absence of drug
selection [29]. To assess whether an eﬃcient transgene deliv-
ery and persistence transgene expression can be achieved
in neural progenitor cells, we ﬁrst overexpressed the eGFP
reporter gene in cNPCs as a proof of principle. Here we show
that eGFP can be eﬃciently delivered to cNPCs using regular
transfection methods. These cells continued to express eGFP
for more than 60 days without signiﬁcant loss of the eGFP
expression. We then overexpressed GDNF in cNPCs and
showed that transgenic cNPCs produced elevated levels of
GDNF in the culture media and retained their identity of
neural progenitors.
2.MaterialandMethods
2.1. Culture of Cat Neural Progenitor Cells (NPCs). Primary
cNPCs were derived from the brains of 47-day cat fetuses
as previously described [8]. For the present work, a frozen
sample of cNPCs at passage 9 (P9) was thawed and
cultured in Ultraculture medium (Lonza, Walkersville, MD),
supplemented with 2mM L-glutamine, 20ng/mL epider-
mal growth factor (human recombinant EGF; Invitrogen,
Carlsbad, CA), and 20ng/mL basic ﬁbroblast growth factor
(human recombinant bFGF; Invitrogen). The complete
Ultraculture-based medium is designated UM. Cells were
passaged every 3-4 days.
2.2. Transfection of cNPCs with pCAG-PyF101-eGFP. The
pCAG-PyF101-eGFP plasmid was puriﬁed using a QIAprep
spin maxiprep kit (QIAGEN, Valencia, CA). Plasmid trans-
fection was performed using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA) following the manufacturers’
instructions. Brieﬂy, 2 million cNPCs were seeded into a T25
culture ﬂask and allowed to grow overnight. Separately, 8mg
of plasmid DNA and 20uL of Lipofectamine 2000 reagent
were each individually diluted in 0.5mL of Ultraculture-
based proliferation medium (UM, as described above),
mixed, and allowed to stand for 5min. The diluted DNA
and Lipofectamine 2000 were then combined, mixed, and
allowed to stand for another 20min. Meanwhile, the T25
ﬂask containing cNPCs was washed once with fresh UM,
which was replaced entirely with another 2mL of fresh UM.
The transfection mixture was added dropwise and mixed.
The ﬂask was kept in a cell culture incubator under standard
conditions (37◦C, 5% CO2) for 48h. Cells were subsequently
reseededintotwoT25ﬂasks,andselectionwasperformedvia
the addition of 1.0ug/mL puromycin to the culture medium
for a duration of at least two weeks. The expression of
eGFP by transfected cNPCs was monitored by ﬂuorescence
microscopy and photographed daily.
2.3. pCAG-PyF101-GDNF Plasmid Construction and Trans-
fection of cNPCs. To construct pCAG-PyF10-GDNF, the
original plasmid pCAG-PyF101-eGFP was digested with
NotI/XhoI. The digested eGFP fragments were excised and
replaced with human GDNF BstbI/NotI fragment from
pEX-Z0010-Lv31 (GeneCopoeia, Germantown, Maryland)
by blunt ends ligation. pCAG-PyF101-GDNF transfection of
cNPCs was performed in the same manner used for pCAG-
PyF101-eGFP, as described above.
2.4. Cell Growth Assessment Using IncuCyte Live Cell Monitor-
ing System. The growth properties of pCAG-PyF101-GDNFStem Cells International 3
Table 1: Primary antibodies used for immunocytochemistry on cNPCs.
Target Antibody type Reactivity in retina Source Dilutions
Nestin Mouse monoclonal Progenitors, reactive glia BD 1:200
Vimentin Mouse monoclonal Progenitors, reactive glia Sigma 1:200
Ki-67 Mouse monoclonal Proliferating cells BD 1:200
GFAP Mouse monoclonal Astrocytes, reactive glia Chemicon 1:200
β3-tubulin Mouse monoclonal Immature neurons Chemicon 1:200
GDNF Rabbit polyclonal Growth factor SCBT 1:200
transfected and nontransfected cNPCs were assessed by
culturingcellsunderproliferationconditionsinultraculture-
based medium (UM). Cells of identical passage number
(P17) were seeded in a 24-well plate at a density of
40,000cells/well. Cells were photographed and counted at
24h intervals, based on 2 distinct measures, namely, nuclear
counts and percentage conﬂuency. Both parameters were
measuredusinganIncuCyte(EssenInstruments,AnnArbor,
Michigan) live cell monitoring system installed within the
incubator. For nuclear counts, triplet wells were labeled
using the nuclear-speciﬁc ﬂuorescent dye Vybrant DyeCycle
Green Stain (Molecular Probes, Invitrogen), which binds to
double-stranded DNA in viable cells. The dye was added
to cultures 30min prior to assessment and nuclear proﬁles
counted using the proprietary IncuCyte program at 24, 48,
72,and96hafterseedingofcells.Cellswerealsomeasuredby
percentage conﬂuency at the same time points, again using
the proprietary IncuCyte program.
2.5. Diﬀerentiation of cNPCs In Vitro. To diﬀerentiate
cNPCs,thecellswereculturedinultraculture-basedmedium
containing 10% FBS but not recombinant growth factors
(UM-FBS) for a period of 5–15 days, prior to further analysis
via FACS, ICC, or ELISA.
2.6. Fluorescence-Activated Cell Sorting (FACS) Analysis.
For FACS analysis, puromycin-selected pCAG-PyF101-eGFP
transfected and nontransfected cNPCs were seeded in T25
ﬂasks (0.25million cells/ﬂask) and cultured for 7 days in
either UM or UM-FBS. Cells were then harvested and
ﬁltered through cell strainer caps (35-μm mesh) to obtain
a single-cell suspension (approximately 106 cells/mL). Cells
were analyzed in an automated manner using a FACSAria
(BD Biosciences, San Diego, CA) and FACSDiva software
(BD Biosciences), without need for cell labeling or nuclear
dyes.TheGFPﬂuorochromewasexcitedbythisinstrument’s
standard 488nm laser, while ﬂuorescence was detected using
a 510/20ﬁlter.
2.7. ELISA Analysis. Plasmid pCAG-PyF101-GDNF trans-
fected cNPCs were cultured in UM or UM-FBS, and
the eﬀects of diﬀerentiation on transgene expression were
assessed by ELISA. In the case of undiﬀerentiated cNPC
controls, cells were seeded in T25 culture ﬂasks in UM and
allowed to grow for one or three days. At the end of days 1
and 3, culture media were replaced with 4mL of fresh UM.
Twenty four hours later, conditioned media were collected,
and cultured cells were counted and collected at days 2 and
4 for ELISA analysis. For diﬀerentiated cNPCs, cells were
seeded in T75 culture ﬂask and cultured in UM-FBS for
7 days. Fresh UM-FBS medium was exchanged at day 6,
and, 24h later, conditioned medium was collected for ELISA
analysis. Cells were also counted and collected for ELISA.
ELISA analysis was performed using a human GDNF
DuoSet ELISA kit and protocol from R and D systems
(Minneapolis, MN). Wells of microtiter plates were coated
(overnight, room temperature) with 2μg/mL of GDNF cap-
ture antibody in 100μL of coating buﬀer (0.05M Na2CO3,
0.05M NaHCO3, pH 9.6). Blocking was performed with
1% BSA in PBS for 1h at room temperature. Samples
(100μL) were loaded in triplicates and incubated for 2h
at room temperature, followed by the addition of 100μL
antibody detection antibody (0.1μg/mL) for additional 2h
at room temperature. HRP-conjugated streptavidin (1:200)
in blocking buﬀer was added (20min, room temperature),
and the reaction was visualized by the addition of 100μLo f
substrate solution and incubation for 20min. The reaction
was stopped with 50μLH 2SO4, and absorbance at 450nm
wasmeasuredwithreductionat540nmusinganELISAplate
reader. Plates were washed ﬁve times with washing buﬀer
(PBS, pH 7.4, containing 0.1% (v/v) Tween 20) after each
step. As a reference for quantiﬁcation, a standard curve was
establishedbyaserialdilutionofrecombinantGDNFprotein
(31.25pg/mL–2.0ng/mL).
2.8. Immunocytochemistry. Transfected and nontransfected
cNPCs were seeded on 4-well chamber slides (Nalge Nunc
International, Rochester, NY) and allowed to grow for
3–5 days. Cells were ﬁxed with freshly prepared 4%
paraformaldehyde (Invitrogen, Carlsbad, CA) in 0.1M
phosphate-buﬀered saline (PBS) for 20min at room temper-
ature and washed with PBS. Cells on slides were incubated in
antibody blocking buﬀer (PBS containing 10% (v/v) normal
goat serum (NGS) (BioSource, Camarillo, CA), 0.3% Triton
X-100, 0.1% NaN3 (Sigma-Aldrich, Saint Louis, MI)) for
1h at room temperature. Slides were then incubated with
primary antibodies at proper dilutions (Table 1) overnight
at 4◦C. The next morning, after washing, slides were incu-
bated in ﬂuorescent-conjugated secondary antibody (Alexa
Fluor546-goat anti-mouse/rabbit, 1:800 in PBS, BD) for
1h at room temperature. After an additional wash, slides
were mounted using DAPI-containing Vectashield Hard Set4 Stem Cells International
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Figure 1: GFP expression in cNPCs transfected with pCAG-PyF101-eGFP plasmid. Transfected cNPC (passage 21) were maintained under
proliferation conditions (UM) or switched to growth factor-free diﬀerentiation conditions (UM + 10% FBS) to evaluate potential loss of
transgene expression. Cultures were photographed at 6, 7, 10, and 15 days. Sustained expression of green ﬂuorescence protein (GFP) was
observed for both conditions at all time points. Paired images are shown for each time point and include phase contrast (a, c, e, g, i, k, m, o)
a n dﬂ u o r e s c e n c e( b ,d ,f ,h ,j ,l ,n ,p )m i c r o g r a p h so ft h es a m ea r e a si nc u l t u r e .
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Figure 2: FACS analysis of GFP expression in nontransfected and transfected cNPCs. FACS analysis was performed on nontransfected and
transfected cNPCs to show the expression of the GFP reporter gene. The vertical axis shows cell count, and the horizontal axis shows relative
ﬂuorescence. (a) Nontransfected cNPCp25 cultured in UM; (b) transfected cNPCp25 cultured in UM; (c) transfected cNPCp25 cultured in
UM containing 10% FBS for 7 days (a) and 15 days (b).Stem Cells International 5
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Figure 3: Growth of nontransfected and pCAG-PyF101-eGDNF plasmid transfected cNPCs. The ﬂuorescence stained nuclei of (a)
transfected and (b) nontransfected cNPCs. cNPCs were cultured in 24-well plate in UM for 4 days. Cells were labeled with a marker for
nuclear DNA, and an IncuCyte live cell monitoring system was used to assess the growth rate of cells on each day. (a) GDNF-transfected
cNPCs; A1–4: Day1–4. (b) Nontransfected cNPCs; B1–4: Day1–4. (c, d) Growth curves of GDNF-transfected and nontransfected cNPCs
(labeled GDNF and Ctl, resp.) imaged and analyzed using an IncuCyte live cell monitoring system. Cells were stained with Vybrant Dycycle
ﬂuorescence nuclear-speciﬁc dye daily for 4 consecutive days (c). At the same time, cells in duplicate sets of wells without nuclear stain were
measured for percentage cell conﬂuency (d). The tight grouping of control data in (d) makes it diﬃcult to discern Ctl1, which is present in
the upper group and reaches conﬂuence rapidly along with the other nontransfected cNPCs. IncuCyte programs were used for both analyses
(c, d).
Mounting Medium (Vector laboratories, Burlingame, CA)
for 20min at room temperature. Negative controls for
immunolabeling were performed in parallel using the same
protocol but without primary antibody. Fluorescent labeling
was judged as positive only with reference to the negative
controls. Immunoreactive cells were visualized and imaged
using a Nikon ﬂuorescent microscope (Nikon, Eclipse E600,
Melville, NY).
3. Results
3.1. Ubiquitous and Constitutive Reporter Gene Expression
in eGFP-Transfected cNPCs. Expression of eGFP in pCAG-
PyF101-eGFP transfected cNPCs was monitored by ﬂuo-
rescence microscopy to assess the transfection eﬃciency
of the plasmid vector. Transfected cells began to exhibit
eGFP-related ﬂuorescence at 18h following-transfection.6 Stem Cells International
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Figure 4: The amount of GDNF produced by nontransfected
and transfected cNPCs measured by ELISA. Nontransfected and
transfected cNPCs were seeded in UM. Culture media were
refreshed 24 hours prior to collection of conditioned media for
ELISA. Samples of culture media conditioned by transfected or
control cells were analyzed to determine the level of GDNF present.
Error bars = SEM.
The percentage of cells expressing eGFP reached approxi-
mately 40% by day 3. At the end of day 3, cells were reseeded,
and puromycin (1ug/mL) was added to the culture medium
in order to select for stable transfectants. After 2 weeks
of drug selection, a preponderance of the surviving cells
expressed eGFP (as demonstrated by FACS analysis below).
ContinuedpropagationofthesecellsinUMformorethan60
days showed that eGFP expression was ubiquitously retained
in the cells.
3.2. Sustained eGFP Transgene Expression under Diﬀeren-
tiation Conditions. To evaluate the inﬂuence of cellular
diﬀerentiation on transgene expression, transfected cNPCs
(atP21)wereculturedinUMcontaining10%FBSforatleast
two weeks. Fluorescence microscopy detected eGFP expres-
sion in almost every cell, indicating that the transfection
procedure was eﬃcient and that the pCAG-PyF101-eGFP
plasmids were stably maintained and actively transcribed
withoutsigniﬁcant attenuationduetocelldivision orgrowth
under in vitro diﬀerentiation conditions (Figure 1).
Flow cytometric analysis was performed to further
conﬁrm eGFP expression in transfected cNPCs. Almost
all transfected cNPCs cultured in either UM or UM
containing 10% FBS (diﬀerentiation medium) expressed
eGFP (Figure 2). Interestingly, eGFP ﬂuorescence intensity
increasedintransfectedcellsculturedinUMcontaining10%
FBS.Wealsodetectedtwosubpopulationsoftransfectedcells
that expressed eGFP at diﬀerent levels (“high” and “medium
high”). This observation may relate to the heterogenous
morphology and size distribution of diﬀerentiating cells,
some of which are larger in size which might serve to dilute
the eGFP concentration within the cell.
3.3. Overexpression of GDNF in cNPCs. To further demon-
strate the application of the pCAG vector for eﬃcient
transgene delivery beyond an eGFP reporter, we next overex-
pressed human GDNF in cNPCs. The eﬀect of transduction
on cellular proliferation was evaluated using an IncuCyte live
cell monitoring system, allowing sequential observation of
cell number in undisturbed cultures (Figures 3(a) and 3(b)).
Both transfected and nontransfected cNPCs were seeded in
24-well plates in UM. Cell numbers were evaluated in terms
of nuclear count and assessment of relative conﬂuence (per-
centage). The resulting data showed that transfected cNPCs
continued to proliferate, albeit at a slower rate than that of
nontransfected cNPCs (Figures 3(c) and 3(d)). Interestingly,
the monolayer cultures of the GDNF-transfected cNPCs
appeared to be healthier, with fewer ﬂoating cells, less cell
clumps, and minimal evidence of cell death.
3.4. Conﬁrmation of Increased GDNF Protein Production by
TransfectedcNPCs. Thelev elso fGDNFp r od uc edb yGDNF -
transfected cNPCs were measured by ELISA. Cells were
culturedinUMorUMcontaining10%FBS,andfreshmedia
wereadded24hourspriortocollectionofconditionedmedia
for ELISA analysis. The data showed that GDNF-expressing
cNPCs produced large amount of GDNF, even 60 days after
initial transfection. In addition, cells cultured in UM as well
as those cultured in UM containing 10% FBS produced
similar amounts of GDNF (Figure 4), indicating that GDNF
expression was maintained under in vitro diﬀerentiation
conditions. We also determined the level of GDNF present
within transfected cells. ELISA indicated that intracellular
GDNF level was low (<10ng/106 cells/day, data not shown)
compared to the amount of GDNF present in culture media
(227–258ng/106 cells/day). Therefore the majority of GDNF
produced was secreted into the culture media.
3.5. Immunocytochemistry Conﬁrms GDNF and Absence of
Treatment-Related Changes in cNPCs. Immunocytochemical
analysis was performed to conﬁrm elevated GDNF pro-
tein expression within treated cNPCs and to evaluate the
potential eﬀects of pCAG transduction and GDNF over-
expression on the ontogenetic status and lineage potential
of the cells. First, an anti-GDNF antibody was used to
detect GDNF protein in transfected cNPCs (Figure 5). This
showedthatGDNFexpressionwasmodestinnontransfected
cNPCs (Figure 5(a)), but was strongly expressed in the
transfected cells (Figure 5(b)). Although GDNF protein was
also prominent in FBS-treated cNPCs, the ﬂuorescence level
was weaker, implying a more dilute distribution of GDNF,
perhaps reﬂecting the larger size of the diﬀerentiating cells
(Figure 5(c)).
Immunocytochemical analysis of a range of neural pro-
genitor markers showed that GDNF overexpression did not
signiﬁcantly aﬀect the expression of neural progenitor and
proliferation markers (Figure 6). Thus, GDNF-expressing
cNPCs retained their identity as neural progenitors.
4. Discussion
Here we report the use of a nonintegrating, plasmid-
based vector to eﬀectively transfect neural progenitor cellsStem Cells International 7
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Figure 5: GDNF expression proﬁles in nontransfected and transfected cNPCp19. GDNF expression proﬁles were evaluated by
immunocytochemistry (ICC) on cNPCs using an anti-human rabbit poly clone antibody. (a) Nontransfected cNPCs in UM; (b) pCAG-
PyF101-GDNF plasmid transfected cNPCs in UM; (c) pCAG-PyF101-GDNF plasmid transfected cNPCs in UM containing 10% FBS for 5
days.
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Figure 6: Expression proﬁles of marker genes in transfected cNPCs by ICC. Gene expression proﬁles of several neural progenitor, cell
proliferation, and diﬀerentiation markers were evaluated by immunocytochemistry (ICC). Transfected cNPCs were cultured in UM, or UM
containing 10% FBS, for 5 days and then immunolabeled with diﬀerent epitope-speciﬁc antibodies to detect the markers shown.8 Stem Cells International
with an exogenous gene encoding a neuroprotective growth
factor. Speciﬁcally, this plasmid vector, also containing the
CAGGhybridpromoterandpolyomavirusmutantenhancer
PyF101a, was used to deliver the human GDNF gene to
progenitor cells cultured from the fetal cat brain (cNPCs).
This is one of the few studies investigating the genetic
modiﬁcation of NPCs derived from nonrodent, nonprimate
mammalian species [24] and the ﬁrst study to demonstrate
the applicability of plasmid-based vector technology to feline
NPCs.
Gene transfer represents a powerful tool for enhancing
the desired characteristics of a therapeutic cell type. Early
workexploitingtransgenicreportergenesanddiseasemodels
has been followed by more ambitious strategies, including
cytokine delivery, immune modulation, and, more recently,
cellular reprogramming [31, 32]. Nevertheless, the enthu-
siasm surrounding these advances has been tempered by
the realization that integration of exogenous transgenes into
the recipient genome can result in signiﬁcant complications,
including malignant transformation of cells and death of
treated patients. For this reason, the use of a nonintegrating
plasmid-based vector is of interest in that it might avoid the
potential adverse perturbations of host cell gene regulation
associated with uncontrolled alteration of the chromosomal
DNA-coding sequence.
One challenge connected with the use of nonintegrating
vectors is the transcriptional silencing of nonchromosomal
DNA sequences by host cells. Use of the highly transcribed
chicken β-actin [33] and its derivative composite promoter
CAGG has recently gained popularity as a strategy for
countering this phenomenon, providing a robust tool for
deriving long-term constitutive transfectants [29, 30, 33,
34]. The ﬁndings of the current study demonstrate that, in
combination, the plasmid-based vector system and CAGG
promoter can eﬀectively transfect feline NPCs. These results
suggest that this method could ﬁnd applicability in the
delivery of various other genes of interest to feline NPCs,
as well as possibly other feline cells, and immature and
diﬀerentiated cells from additional mammalian species.
One interesting observation is that the GDNF-
transfected cells exhibited a slower growth curve than
untransfected controls. The reason for this was not
delineated in the current study, but could relate to a
number of considerations. One of these is that the cells
were genetically manipulated and this could be deleterious
in a number of ways. Another is that the cells overexpress
the signaling molecule GDNF, which could in turn exert
physiological inﬂuences on apoptosis or rate of proliferation.
In another study with murine retinal progenitor cells [35],
we showed that exogenous GDNF was antiapoptotic and did
not impede proliferation, suggesting that the slower growth
seen in the current study likely results from the genetic
modiﬁcation process or resultant protein overexpression,
rather than from subsequent GDNF-induced signaling.
The cells generated and banked during this study provide
a uniquely modiﬁed cell type with potential scalability. As
such, these genetically modiﬁed feline NPCs could be of
translational interest in the setting of veterinary applications.
Furtherstudiesinvolving transplantationwillbenecessaryto
explore the safety and therapeutic potential of these cells. In
termsoffelineretinaldegeneration,asuitablerecipientexists
in the form of the retinal dystrophic Abyssinian cat [8].
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